Data Security
All aggregate, de-identified data were housed in the NCCN Breast Oncology Outcomes Database via individual institutional review board (IRB)-approved protocols, with an institution-specific identifier key known only to that institution. Patient-level performance data on individual measures were provided to the institution in a "locked" state so that only members of the individual institution, under an IRB-approved protocol, could "unlock" patient-specific data to identify measure-specific performance.
Methods
Baseline data were provided to the institution as indicated in Table 2 in spring 2011. Because the results at the institution were less than the targeted concordance rate of 85%, the measures chosen for attention were inva4a, inva9a, and JVBis1. The OFI group normalized definitions for guideline nonconcordance, as noted in the following sections.
Physician Discussed, Patient Declined
For each case of a patient decision to decline guidelineconcordant care, there should be 1) source documentation of the provider's recommendation of the guideline-concordant care, and 2) documentation that the patient or patient's guardian declined care. If possible, a record of the discussion with the patient should be documented and reviewed to ensure adequate patient education was provided. est contributors to the discordance rate originally reported were 1) data entry error (N=43), an indication of the difficulty in locating the correct data source in unstructured medical record sources; 2) patient choice (N=16), which seemed, from the medical record review, more of an indication of informed patient choice rather than a true error in treatment recommendation or communication; and 3) comorbidity or advanced age (N=11), which, reflects that the NCCN Guidelines are written as guidelines and must be interpreted in light of other competing medical issues.
Physician-Related

Conclusions
Although measuring performance against standardized norms and looking for relevant opportunities to improve are important, current data limitations must also be considered. Despite the formal definitions used in this effort and the involvement of experienced data abstractors with a strict database structure, subsequent clinical review showed results that were only approximations to reality. At this institution, a 5% to 15% variance was noted between initial review and intensive subsequent review, mostly due to system limitations. Patient choice and comorbidities will also contribute to variation concordance. Given these limitations, seeking 100% concordance with any guideline is probably unrealistic. The appropriate target of concordance may be very situation-specific. in a nonconcordant status. The error should be noted and appropriate personnel notified to correct the data. Unknown or Analytic Error: This category is used for each case deemed to be concordant when the reason the case was classified as nonconcordant is unknown. The error should be noted and the personnel notified to work with project management to determine the underlying reason.
Results
Detailed individual chart review was performed by experienced data abstractors (Table 2) , following the previously noted standardized definitions. A third review was performed by 2 medical oncologists with experience in reviewing data for quality measurement to better understand the reasons for nonconcordance.
Because of the lack of structured clinical data entry at this institution, the volume of clinical documents, the formatting of documentation both internally (inpatient notes) and externally (referral and follow-up notes) into scanned documents, and the multiple data sources required to review some of the data elements, such as order entry and administration (for the bisphosphonate measure), the OFI team felt this review should be performed by qualified physicians. This review required 30 to 45 minutes for each case previously scored as nonconcordant.
The intensive, focused, physician-only review of all documentation from all sources in the medical record showed a "real" concordance rate across all measures of 91% (range, 82%-97%). The 3 larg-
